These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 17159852)

  • 1. [Effect of eprosartan on psychophysiological functions of drivers with arterial hypertension].
    Tsfasman AZ; At'kova EO; Gutnikova OV
    Kardiologiia; 2006; 46(10):18-20. PubMed ID: 17159852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eprosartan: a review of its use in the management of hypertension.
    Robins GW; Scott LJ
    Drugs; 2005; 65(16):2355-77. PubMed ID: 16266204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of eprosartan on thrombocytes aggregative capacity in patients with arterial hypertension and metabolic syndrome].
    Simonenko VB; Medvedev IN; Kumova TA
    Klin Med (Mosk); 2008; 86(4):19-21. PubMed ID: 18494280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Stress-associated hypertension in the work place: results of the STARLET project].
    Lüders S; Hammersen F; Kulschewski A; Frerichs A; Frieg R; Hahnheiser D; Reich G; Schnieders M; Schrandt G; Schrader J
    Dtsch Med Wochenschr; 2006 Nov; 131(46):2580-5. PubMed ID: 17096303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ambulatory monitoring of systolic hypertension in the elderly: Eprosartan/hydrochlorothiazide compared with losartan/hydrochlorothiazide (INSIST trial).
    Ambrosioni E; Bombelli M; Cerasola G; Cipollone F; Ferri C; Grazioli I; Leprotti C; Mancia G; Melzi G; Mugellini A; Mulè G; Palasciano G; Salvetti A; Trimarco B
    Adv Ther; 2010 Jun; 27(6):365-80. PubMed ID: 20556561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction.
    de la Sierra A; Ram CV
    Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S1-3. PubMed ID: 18093407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Teveten (eprosartan) reduces future risk in hypertensive stroke patients.
    Cardiovasc J S Afr; 2004; 15(5):255-6. PubMed ID: 15483740
    [No Abstract]   [Full Text] [Related]  

  • 8. Costs of eprosartan versus diuretics for treatment of hypertension in a geriatric population: an observational, open-label, multicentre study.
    Gregori JA; Nuñez JF; Domínguez-Gil A;
    Drugs Aging; 2009; 26(7):617-26. PubMed ID: 19655828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eprosartan effect on fibrinolytic/hemostatic variables in arterial hypertension: a comparative study to losartan.
    Makris TK; Stavroulakis G; Papadopoulos DP; Krespi P; Hatzizacharias A; Zilidis A; Tsoukala C; Votteas VE
    Drugs Exp Clin Res; 2004; 30(3):125-32. PubMed ID: 15366789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).
    Schrader J; Lüders S; Kulschewski A; Hammersen F; Plate K; Berger J; Zidek W; Dominiak P; Diener HC;
    Stroke; 2005 Jun; 36(6):1218-26. PubMed ID: 15879332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antihypertensive effects and safety of eprosartan: a meta-analysis of randomized controlled trials.
    Xu FY; Yang B; Shi D; Li H; Zou Z; Shi XY
    Eur J Clin Pharmacol; 2012 Feb; 68(2):195-205. PubMed ID: 21881888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effects of telmisartan and eprosartan on insulin sensitivity in the treatment of overweight hypertensive patients.
    Fogari R; Zoppi A; Ferrari I; Mugellini A; Preti P; Lazzari P; Derosa G
    Horm Metab Res; 2009 Dec; 41(12):893-8. PubMed ID: 19708000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eprosartan: a review of its use in hypertension.
    Plosker GL
    Drugs; 2009; 69(17):2477-99. PubMed ID: 19911859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unique dual mechanism of action of eprosartan: effects on systolic blood pressure, pulse pressure, risk of stroke and cognitive decline.
    Ram CV; Rudmann MA
    Expert Rev Cardiovasc Ther; 2007 Nov; 5(6):1003-11. PubMed ID: 18035916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eprosartan-based hypertension therapy, systolic arterial blood pressure and cognitive function: analysis of Middle East data from the OSCAR study.
    Radaideh GA; Choueiry P; Ismail A; Eid E; Berrou JP; Sedefdjian A; Sévenier F; Pathak A
    Vasc Health Risk Manag; 2011; 7():491-5. PubMed ID: 21915165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension.
    Delles C; Jacobi J; John S; Fleischmann I; Schmieder RE
    Kidney Int; 2002 Apr; 61(4):1462-8. PubMed ID: 11918753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical profile of eprosartan: a different angiotensin II receptor blocker.
    Blankestijn PJ; Rupp H
    Cardiovasc Hematol Agents Med Chem; 2008 Oct; 6(4):253-7. PubMed ID: 18855637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin blockade with eprosartan: vascular and functional implications.
    Ram CV
    Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S5-11. PubMed ID: 18093408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does the MOSES study provide sufficient evidence for Eprosartan against Nitrendipine?
    Larsen K; Hornnes N; Boysen G
    Stroke; 2006 Jun; 37(6):1357; author reply 1358. PubMed ID: 16645128
    [No Abstract]   [Full Text] [Related]  

  • 20. Celiac disease-like enteropathy due to antihypertensive therapy with the angiotensin-II receptor type 1 inhibitor eprosartan.
    Maier H; Hehemann K; Vieth M
    Cesk Patol; 2015; 51(2):87-8. PubMed ID: 25970720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.